Drug Extends Head and Neck Cancer Survival Feb 8, 2006
8 (HealthDay News) -- Adding the drug cetuximab to radiation therapy for head and neck cancer can boost patient survival rates by about 20 months without ... - Forbes
Metastatic Gastric Cancer Patients Respond to Cetuximab Plus ... Jan 30, 2006
2006 -- At least 80% of patients with metastatic gastric cancer appear to achieve some clinical benefit from a chemotherapy regimen in which cetuximab is added ... - DG News
Erbitux-Based Chemoradiation May Help in Head-and-Neck Cancer Feb 8, 2006
8 - Erbitux (cetuximab) combined with radiotherapy may be a viable alternative for patients with head-and-neck cancer who can't tolerate platinum-based ... - MedPage Today,
Give us all wonder drugs now Feb 7, 2006
To cut corners would be highly irresponsible.". CETUXIMAB a last-stage treatment for patients with advanced colorectal cancer. Although ... - ic NorthWales,
Meditech to Showcase Cancer Research at International Forum Feb 2, 2006
...preeminent. cetuximab (Erbitux®). ... that. we’ve generated using the HyACT™ platform with drugs such as cetuximab and gemcitabine.�. - PharmaLive.com (press release),
'I've been given an early death sentence' Jan 17, 2006
...the Washington grandad has been told his illness is now terminal – but he believes his life may have been prolonged if he was given the drug, Cetuximab. ... - Sunderland Echo,
Local cancer centers starts new clinical trial Jan 18, 2006
However, only one of the groups will receive an additional antibody called Cetuximab. Cetuximab has been approved by the Food & ... - Orlando Business Journal,
How and why we pay for the medicines we need Jan 30, 2006
In the most recent cases, applications for the colorectal anti-cancer drug cetuximab have been refused on the grounds that Nice has yet to issue guidance. ... - ic Wales,
MP condemns postcode lottery on drugs Feb 2, 2006
...on "humanitarian grounds". Mr Wilson, 66, is suffering from bowel cancer but has been refused Cetuximab by the NHS. Mr Fergus, who ... - ic Teesside.co.uk,
Pharmaceutical Companies Look to Biomarkers to Help in Increasing ... Feb 2, 2006
...for molecularly targeted oncology drugs, including trastuzumab (Genentech's Herceptin), imatinib mesylate (Novartis's Gleevec), and cetuximab (ImClone's Erbitux ... - PharmaLive.com (press release),
Hundreds of cancer patients denied best drugs Jan 7, 2006
...cancer patients are now funding their treatment themselves, while some other patients have been accepted on a clinical trial for the bowel cancer drug Cetuximab ... - ic Wales,
Workmates to fund pal's cancer treatment Jan 7, 2006
...drug. Paul Cook’s doctor recommended he be treated with Cetuximab for bowel cancer after unsuccessful courses of chemotherapy. ... - ic Wales,
The prescriptions patients want Jan 7, 2006
...year; Cetuximab - is used as a last-stage treatment for patients with advanced colorectal cancer, when other treatments have failed. ... - ic Wales,
NCCN Announces Important Updates to Several Clinical Practice ... Jan 30, 2006
...chemoradiation. Cetuximab (Erbitux, BMS/ImClone) is now included as a treatment option for recurrent or unresectable Head and Neck Cancers. ... - Genetic Engineering News,
B-MS sales dip in Q4 on Pravachol competition Jan 26, 2006
Other products offsetting the impact of generic competition were colorectal cancer drug Erbitux (cetuximab), Reyataz (atazanavir) for HIV, and the ... - Pharma Times (subscription),
Amgen slumps despite robust Q4 figures Jan 27, 2006
...reporting interim clinical data on panitumumab, a drug for colorectal cancer that will compete in the marketplace with ImClone's Erbitux (cetuximab), sold by ... - Pharma Times (subscription),
Cancer pals pledge Jan 8, 2006
Dad-of-one Paul Cook's doctor recommended he be treated with Cetuximab for bowel cancer after unsuccessful courses of chemotherapy. ... - ic Wales,
No WAG cash for cancer drugs Jan 11, 2006
Velindre Hospital revealed that every request they had made for patients to be funded for drugs such as Herceptin and the bowel cancer drug Cetuximab had been ... - ic Wales,
Xanthus: more hurdles to clear for Symadex Jan 17, 2006
Recent entrants such as Genentech/Roche's Avastin (bevacizumab) and ImClone/Bristol-Myers Squibb/Merck KGaA's Erbitux (cetuximab) have also significantly ... - Pharmaceutical Business Review
